ASTH — Astrana Health, Inc.

Summary of Astrana Health's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $965.1 million, up 56% year-over-year.
• Adjusted EBITDA: $66.3 million, up 82% year-over-year.
• Non-GAAP Adjusted EPS: $0.74, up 76% year-over-year.
• Free Cash Flow: Approximately $64 million.
• Net Leverage: Reduced to approximately 2.3x on a pro forma basis, down from 2.6x at year-end 2025.
• Membership: Approximately 1.55 million members in value-based care arrangements, with 40% of owned membership in full risk contracts.

2. Strategic Updates and Business Highlights

• Astrana is leveraging its AI-enabled platform and payer-agnostic care model to improve care delivery, data integration, and financial accountability.
• The company emphasized the importance of its integrated operating system, which enhances patient engagement and operational efficiencies.
• Integration of Prospect is on track, with gross provider retention above 99% and synergy targets of $12 million to $15 million expected to be met.
• The company reported improved medical cost trends, outperforming its full-year assumption of approximately 5.2%, with favorable performance across both core and legacy populations.

3. Forward Guidance and Outlook

• 2026 Full-Year Guidance:
  • Revenue expected between $3.8 billion and $4.1 billion.
  • Adjusted EBITDA between $250 million and $280 million.
  • Free cash flow between $105 million and $132.5 million.
• Q2 2026 Guidance:
  • Revenue expected between $965 million and $1 billion.
  • Adjusted EBITDA between $65 million and $70 million.
• The company maintains a conservative outlook on Medicaid membership trends and expects to provide updates on the Quality Assurance Fund later in the year.

4. Bad News, Challenges, or Points of Concern

• Medicaid Membership: Slightly below expectations with higher attrition rates, although acuity remains favorable.
• Exchange Enrollment: Disenrollment rates tracking ahead of expectations, with current projections indicating a decline of 20% to 30% instead of the previously anticipated 30% to 40%.
• Regulatory Environment: Ongoing changes in Medicare Advantage risk adjustment models may pose challenges, although Astrana believes it is well-positioned due to its conservative approach.

5. Notable Q&A Insights

• Enrollment Trends: Management provided detailed updates on enrollment and trends across Medicare, Medicaid, and exchange populations, noting better-than-expected performance in some areas.
• Capital Allocation: Discussion on the potential uses of excess cash, including organic investments, M&A opportunities, and share repurchases, with a focus on disciplined capital allocation.
• AI Investments: Management highlighted the impact of AI on operational efficiencies, particularly in reducing G&A costs, while also noting ongoing investments in clinical workflows.
• Future of Risk Adjustment: Management expressed optimism about the potential for AI-inferred risk scores in future Medicare Advantage models, suggesting that Astrana's conservative approach may yield advantages.

Overall, Astrana Health reported strong financial performance in Q1 2026, driven by disciplined growth and operational efficiencies, while navigating challenges in membership trends and regulatory changes. The company remains focused on leveraging its integrated platform and AI capabilities to enhance care delivery and financial performance.